IMV Announces First Patient Dosed in the VITALIZE Phase IIB Clinical Study Evaluating its Lead Compound, MVP-S, in Combination with KEYTRUDA^® (pembrolizumab) in Patients with r/r DLBCL

IMV, Inc., a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX platform to treat solid and hematologic cancers, announced a first patient dosed in the VITALIZE Phase IIB clinical trial.